Grant: Collaborative Health Research Projects
McMaster University
$172,416.00
Bioengineered chimpanzee adenovirus-based vaccines against tuberculosis: Optimization of immunologic property, formulation and delivery for bench-to-human applications
EF 2013-14
Résumé
Lung tuberculosis (TB) is one of the leading global infectious causes of death. TB still remains a serious health concern inCanada due to ever-increasing immigrant populations (latent TB), high incidence rates of TB in First Nations communities,and much increased susceptibility to TB by HIV co-infection. The drug-resistant cases have been seen in most Canadianprovinces.BCG, the only TB vaccine, has been used globally for 90 years but it has failed to effectively control global TB epidemic. It isnow believed that BCG will continue to be administered to humans and novel effective immunization strategies are urgentlyneeded for boosting the protective immunity in the lung. In this regard, the work carried out by us and others over the last 10years indicates the bioengineered recombinant virus-based, such as human type 5 adenovirus-based (AdHu5), TB vaccinesto be of promise. However, AdHu5-based vaccines have met with the challenge that the majority of humans have thepreexisting immunity against AdHu5 which may compromise both the safety and efficacy of AdHu5-based immunization.To address this quest, we have formed a strong interdisciplinary Team consisting 2 biomedical vaccinologists, 1 chemicaland 1 medical engineers, and 1 health/infectious disease specialist. Together, we will develop bioengineered chimpanzeeadenovirus-based TB vaccines which are expected to be safe and effective in humans as humans do not have pre-existingimmunity towards them. Various formulations will be developed for enhanced stability. A new way of vaccine delivery to thelung will also be developed. Their safety and efficacy will be evaluated in animal models of TB. The selected candidate willthen be evaluated in humans. The success of our project will be facilitated by participation from two Canadian-basedvaccine corporate partners. Our project is expected to lead to the commercialization of a most promising TB vaccine forimproving the health of Canadians and beyond.
Programme
Collaborative Health Research Projects
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
446321-2013
Name nom
Xing, Zhou
Department département
Pathology and Molecular Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
172416
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
3
Application title
Bioengineered chimpanzee adenovirus-based vaccines against tuberculosis: Optimization of immunologic property, formulation and delivery for bench-to-human applications
Keyword
NSERC
Application summary
Lung tuberculosis (TB) is one of the leading global infectious causes of death. TB still remains a serious health concern inCanada due to ever-increasing immigrant populations (latent TB), high incidence rates of TB in First Nations communities,and much increased susceptibility to TB by HIV co-infection. The drug-resistant cases have been seen in most Canadianprovinces.BCG, the only TB vaccine, has been used globally for 90 years but it has failed to effectively control global TB epidemic. It isnow believed that BCG will continue to be administered to humans and novel effective immunization strategies are urgentlyneeded for boosting the protective immunity in the lung. In this regard, the work carried out by us and others over the last 10years indicates the bioengineered recombinant virus-based, such as human type 5 adenovirus-based (AdHu5), TB vaccinesto be of promise. However, AdHu5-based vaccines have met with the challenge that the majority of humans have thepreexisting immunity against AdHu5 which may compromise both the safety and efficacy of AdHu5-based immunization.To address this quest, we have formed a strong interdisciplinary Team consisting 2 biomedical vaccinologists, 1 chemicaland 1 medical engineers, and 1 health/infectious disease specialist. Together, we will develop bioengineered chimpanzeeadenovirus-based TB vaccines which are expected to be safe and effective in humans as humans do not have pre-existingimmunity towards them. Various formulations will be developed for enhanced stability. A new way of vaccine delivery to thelung will also be developed. Their safety and efficacy will be evaluated in animal models of TB. The selected candidate willthen be evaluated in humans. The success of our project will be facilitated by participation from two Canadian-basedvaccine corporate partners. Our project is expected to lead to the commercialization of a most promising TB vaccine forimproving the health of Canadians and beyond.